

February 20, 2023

To: All Concerned Parties

Company Name: Solasia Pharma K.K.  
Representative: Yoshihiro Arai, President & CEO  
(Code number: 4597, TSE Growth Section)  
Contact: Toshio Miyashita, CFO, Director  
Tel: 81-3-5843-8046

## Announcement Concerning Election of Five Board Directors and One Audit & Supervisory Board Member

Solasia Pharma K.K. (hereinafter "the Company") hereby announces that at a Board of Directors meeting held today, it has resolved to submit a proposal to the 15th Annual General Meeting of Shareholders (the "Annual General Meeting of Shareholders ") to be held on March 23, 2023, for the reappointment of all directors and one corporate auditor as follows.

### 1. Election of Five (5) Directors

The terms of office of all five (5) incumbent Board Directors of the Company will expire at the conclusion of this Annual General Meeting of Shareholders. Therefore, the Company proposes the election of five (5) Board Directors as reappointment of all Directors.

The candidates for Board Director are as follows:

No.	Name	Current position and responsibility in the Company
1	Yoshihiro Arai (Re-election)	President and Chief Executive Officer, Board Director
2	Toshio Miyashita (Re-election)	CFO and Head of Administration Division, Board Director
3	Stanley Lau (Re-election/Outside/Independent)	Board Director
4	Norikazu Eiki (Re-election/Outside/Independent)	Board Director
5	Jiro Mizukawa (Re-election/Outside/Independent)	Board Director

### 2. Election of one Auditor

The terms of office of one incumbent Audit & Supervisory Board Member Susumu Araki will expire at the conclusion of this Annual General Meeting of Shareholders. Therefore, the Company proposes the election of one (1) Audit & Supervisory Board Member as reappointment of Susumu Araki.

# *Solasia*

Disclaimer:

The forward-looking statements, including earnings forecasts, contained in this press release are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Such statements should not be construed as representing commitments on the part of the Company. Please be aware that actual performance may differ for a variety of reasons. Major factors affecting the Company's actual performance include the economic conditions in which it operates, exchange rate fluctuations, the competitive situation and other factors. Information contained in this press release with regard to pharmaceuticals and medical devices (including products under development) is not provided for the purposes of advertising or medical advice.